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BRIEF COMMUNICATION

OPEN

Age-dependent hormesis-like effects of the synthetic
cannabinoid CP55940 in C57BL/6 mice
Erik L. Hodges1, Jessica P. Marshall1 and Nicole M. Ashpole

1,2 ✉

Use of cannabis and cannabinoid-containing substances is increasing among geriatric patients, despite relatively sparse preclinical
evidence in aged models. To better understand the effects of exogenous cannabinoids on aging male and female rodents, we
compared the age- and dose-dependent physiological and behavioral effects of the synthetic cannabinoid CP55940 in young–adult
and aged C57BL/6 mice. Locomotion, body temperature, thermal nociception, and fecal output were measured following CP55940
administration. Our ﬁndings indicate that CP55940 is more potent and efﬁcacious in older mice, evidenced by exaggerated
antinociception and locomotor inhibition when compared to younger adult mice. In addition, we report that low doses of CP55940
paradoxically stimulate locomotion in young–adult (4 m) mice; however, this hormesis-like response is not as evident in aged
animals (21–24 m). These bidirectional effects appear to be mediated via the endocannabinoid CB1 and CB2 receptors.
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INTRODUCTION
Collectively, the canonical receptors (CB1 and CB2), interacting
proteins (cannabinoid receptor interacting protein-1α [CRIP1α]),
endogenous ligands (anandamide and 2-arachidonoylglycerol),
biosynthetic regulators (N-acyl phosphatidylethanolamine phospholipase D [NAPE-PLD], diacylglycerol lipase-α [DAGLα], and
diacylglycerol lipase-β [DAGLβ]), and metabolizing enzymes (fatty
acid amide hydrolase [FAAH] and monoacylglycerol lipase [MGL])
of the endocannabinoid system are known to dynamically
regulate numerous aspects of mammalian physiology. Though
extensive work has been conducted on the behavioral and
developmental effects of exogenous cannabinoids early in life,
substantially less is known regarding the physiological effects of
these substances in advanced age1,2. This lack of information,
coupled with rapidly shifting trends in cannabis- and cannabinoiduse worldwide puts elderly patients particularly at-risk3. Furthermore, emerging evidence suggests that the endocannabinoid
system may play a fundamental role in the biological processes of
aging. This is exempliﬁed by transgenic mice that are genetically
deﬁcient in CB1, which exhibit progeroid cognitive and physiological phenotypes4. However, pharmacological manipulation of
endocannabinoid signaling does not appear to produce consistent effects across the lifespan. This is evidenced in studies where
chronic infusion of the phytocannabinoid Δ-9-tetrahydrocannabinol (THC) was shown to enhance cognition in aged mice at doses
which impair younger animals’ performance5.
Cannabis and cannabinoid-containing substances have been
used therapeutically for millennia, but rigorous evaluation of their
medical value is still ongoing6. In preclinical rodent models, the
effects of CB1-acting compounds are traditionally measured using
the “Tetrad Assay”—a battery of tests that measure locomotion
(open ﬁeld), body temperature (rectal probe), catalepsy (ringimmobility), and nociception (hot plate or tail withdrawal)7,8. The
synthetic cannabinoid CP55940 is a well-documented, highafﬁnity CB1/CB2 mixed agonist, which elicits the hallmark
behaviors tested in these assays. Studies have demonstrated that
the behavioral effects of CP55940 are similar to those produced by

high doses of the phytocannabinoid THC—hypolocomotion,
hypothermia, and antinociception—though CP55940 is substantially more potent and efﬁcacious than THC in these assays9.
While there is consensus regarding the depressant, aversive, and
antinociceptive effects of CB1 agonists at high doses, several studies
report contradictory stimulation of locomotion, body temperature,
and cognitive behaviors at low or ultralow doses1,10–12. One
explanation for these biphasic dose responses is the biological
adaptive response known as hormesis12,13. As deﬁned by
Calabrese and Baldwin, hormesis refers to the manner in which
biological systems adapt to slight environmental perturbations
and subsequently alter their performance14. In the pharmacological context, hormesis may manifest as a nonlinear or bidirectional dose-response, in which low amounts of a substance
produce the opposite effects of higher doses. Though the extent
of low-dose stimulation in these systems is reported to be modest
(30% of vehicle-treated response), the therapeutic application of
pharmacological hormesis in a manner similar to preconditioning
might enhance the resilience of aging systems13.
Hormesis, preconditioning, and bidirectional dose responses are
widely evident in numerous biological systems, though systematic
evaluation of these modest low-dose effects is difﬁcult and
therefore often overlooked. Nevertheless, these ﬁndings are
critical, as hormesis-like effects may rectify conﬂicting results
observed between treatment groups. Regarding exogenous
cannabinoids, several lines of evidence demonstrate that treatment with low doses of these substances beneﬁts cognition in
aged animals; however, administration of these same doses to
younger animals results in cognitive impairments12,15,16. Hormesislike responses to cannabinoids have been reported by several
studies using young animals, though it remains to be seen
whether or not this hormetic responses is consistent throughout
the lifespan1. To test whether the bidirectional, hormesis-like
response to cannabinoids is age-dependent, we experimentally
assessed the dose-dependent physiological and behavioral effects
of CP55940 at multiple doses in young–adult (4 m) and aged
(21–24 m), male and female mice.
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RESULTS
Acclimation to vehicle injection and baseline
In order to adequately capture potential biphasic behavioral and
physiological responses elicited by the synthetic CB1/CB2 agonist
CP55940, we administered this compound via intraperitoneal (IP)
injection at the following weight-adjusted doses: 0.001, 0.01, 0.1,
0.4, and 0.8 mg/kg. Prior to treatment with CP55940, animals
underwent a 6-day acclimation period consisting of 3 days of
handling and temperature measurement, followed by 3 additional
days of temperature recordings before and after vehicle injection
(1:1:18, EtOH:Kolliphor:Saline) (Supplementary Fig. 1). During the
acclimation period, baseline temperature was measured immediately before and 60 min after injection using both a rectal probe
and a non-contact infrared (IR) thermometer. During acclimation
recordings, both young–adult (4 m) and old (21–24 m) mice
showed a slight but consistent average reduction in rectal and IR
temperatures 60 min after injection of the vehicle solution
(Supplementary Fig. 2). In addition, old mice weighed more while
having lower baseline rectal and skin/pelage temperatures than
young–adult mice (Supplementary Fig. 2).
Behavioral and physiological responses to CP55940
On the day of behavioral testing, male and female mice were
injected with varying doses of CP55940 or vehicle then assessed
for locomotor, thermoregulatory, or nociceptive responses. No
sex-speciﬁc differences were observed throughout the study, thus
the data from both males and females were combined. Activity
measurements recorded in the open ﬁeld 30–60 min after
injection indicate that treatment with CP55940 displays a
signiﬁcant age:dose interaction effect on total locomotion
(locomotion~age × dose, H(5351) = 11.451, P = 0.043). Interestingly, young–adult mice treated with the lowest dose of
CP55940 tested (0.001 mg/kg) exhibit signiﬁcantly increased
locomotion compared with age-matched vehicle-treated control
animals (P < 0.05, Fig. 1a). However, old animals administered this
same dose did not signiﬁcantly differ from age-matched vehicletreated
controls.
As
expected,
higher
doses
of
CP55940 signiﬁcantly reduced locomotion in both young–adult
and aged animals, though this suppression was evident in aged
animals at a dose of 0.1 mg/kg, which did not inhibit locomotion
in young–adult animals (Fig. 1a). In both age groups, doses of
CP55940 ≥ 0.4 mg/kg induced severe catalepsy (Fig. 1a). Though
no effect of age was detected on fecal output during the openﬁeld task (feces~age, H(1297) = 1.57, P = 0.210), young vehicletreated animals produced signiﬁcantly more fecal pellets during
the open-ﬁeld task than old control animals (P = 0.004). In
addition, at doses of CP55940 ≥ 0.01 mg/kg fecal output was
signiﬁcantly reduced in both age groups (Fig. 1b).
Immediately following the 60-min temperature recordings,
nociception was quantiﬁed by placing each mouse onto a 52 °C
heated plate, and recording the latency to lick its hind-paw or
jump. Signiﬁcant simple main effects of dose (latency~dose, H
(5353) = 149.41, P < 0.001) and age (latency~age, H(1353) = 9.21,
P = 0.002) were detected in this assay, though no interaction
between these factors was observed (Fig. 1c). Among vehicletreated animals, young mice were signiﬁcantly quicker to respond
than older mice (P = 0.005). The antinociceptive effects of
CP55940 were highly signiﬁcant in both age groups at doses of
0.4 and 0.8 mg/kg, though aged animals were signiﬁcantly slower
to respond than young animals at both of these doses. In later
cohorts of animals, nociception was also assessed via tailimmersion in a hot-water bath (46 °C). The results from these
tests were similar to the hot plate, although no main effect of age
was detected (Fig. 1d). Intriguingly, a signiﬁcant reduction in
latency to withdraw tail was observed in old animals treated with
the intermediate dose of 0.01 mg/kg (P = 0.049). In agreement
npj Aging and Mechanisms of Disease (2020) 7

with the hot plate recordings, age groups showed highly
signiﬁcant antinociception at doses of CP55940 ≥ 0.4 mg/kg.
Rectal and skin/pelage temperatures were measured 60 min
post injection via rectal probe and infrared thermography. Both of
these measures displayed a signiﬁcant main effect of dose during
behavioral testing (Δrectal~dose H(5349) = 182.01, P < 0.001 and
Δskin~dose, H(5340) = 146.06, P < 0.001). In vehicle-treated animals, rectal and skin/pelage temperatures were signiﬁcantly
elevated from baseline in young–adult and old mice (Fig. 1e, f).
When compared with vehicle-injected animals, high doses of
CP55940 (0.4 and 0.8 mg/kg, IP) signiﬁcantly reduced rectal
temperature in both age groups. Importantly, this decline in
rectal temperature was more pronounced in aged mice, which
exhibited reductions in rectal temperature at the dose of 0.1 mg/
kg which had no effect in younger animals.
Responses to CP55940 and CB1 or CB2 antagonism
To determine whether the biphasic effects of CP55940 could be
accounted for by activity at canonical cannabinoid receptors, we
co-administered CP55940 with the CB1 or CB2 inverse agonists—
AM251 or AM630, respectively. Based on previous literature, doses
of 3 mg/kg AM251 or AM630 were administered to modulate CB1and CB2-mediated signaling and behavior17,18. Two doses of
CP55940 shown to stimulate locomotion in young males (0.001
and 0.01 mg/kg, IP) were administered alone or in the presence of
AM251 or AM630; in addition, a high dose (0.8 mg/kg) that
signiﬁcantly reduces locomotion in both young and old animals
was co-administered with AM251 (3 mg/kg). AM251 alone
signiﬁcantly reduced locomotion and attenuated both the
stimulatory and inhibitory effects of CP55940 on locomotion in
young–adult males (Fig. 2a). In contrast, AM630 coadministration
in young males signiﬁcantly attenuated the psychomotor
stimulation elicited by CP55940, but did not block the reduction
in fecal output produced by CP55940 at a dose of 0.01 mg/kg
(Supplementary Fig. 3). The CB1 inverse agonist AM251 also
blocked the inhibitory effects of 0.01 mg/kg CP55940 on fecal
output in young males (Fig. 2c). Fecal output was signiﬁcantly
increased following coadministration of AM251 with 0.8 mg/kg
CP55940 compared with 0.8 mg/kg CP55940 alone; although this
was a partial rescue by AM251, as a signiﬁcant decrease from
vehicle control was still observed during coadministration of the
drugs. Similar to the rescue of locomotor inhibition, the
antinociceptive and hypothermic effects of 0.8 mg/kg CP55940
were abrogated by 3 mg/kg AM251 in young and old mice (Fig.
3a–d), suggesting CB1 mediates these responses to high-dose
synthetic cannabinoid administration.
While aged animals did not show signiﬁcant stimulatory
locomotor effects with low doses of CP55940, we veriﬁed that
the mechanism responsible for the changes observed with high
doses of CP55940 was unchanged in advanced age. Coadministration of CP55940 with AM251 signiﬁcantly attenuated the
hypolocomotor (Fig. 2b), antinociceptive (Fig. 3b), and hypothermic effects (Fig. 3d) of CP55940 in aged males. Similar to the
effects in young–adult males, changes in fecal output were
partially rescued by coadministration of AM251 with CP55940 in
aged males (Fig. 2d), although it is important to note that 3 mg/kg
of AM251 alone signiﬁcantly increased fecal output (Fig. 2d).
AM251 also reduced locomotor activity and signiﬁcantly reduced
body temperature in the aged mice (Figs. 2b and 3d), similar to
the changes seen with AM251 alone in the young males (Figs. 2a
and 3c).
Pharmacokinetics of CP55940 and endocannabinoid gene
expression in the brain
To determine the mechanism for the enhanced potency of
CP55940 seen in aged animals, pharmacokinetic distribution of
CP55940 in the blood and brain was quantiﬁed following either 0.1
Published in partnership with the Japanese Society of Anti-Aging Medicine
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Fig. 1 Effects of CP55940 on locomotion, thermoregulation, and nociception in Young–adult (4 m) and old (22 m) C57BL/6 mice. CP55940
was administered via intraperitoneal injection at doses ranging from 0.001 to 0.8 mg/kg to young and old male and female mice. Individual
data points for each testing group are overlaid on Tukey-style boxplots. The lower and upper edges of each box represent the ﬁrst and third
quartiles, respectively. The middle horizontal line in each box depicts the median of that dose/age group. Sample sizes for every treatment
group and ﬁgure panel are listed in Supplementary Fig. 5. Statistical comparisons of age, dose, and age:dose interactions were made using the
nonparametric Scheirer–Ray–Hare test. Signiﬁcant omnibus results were followed by planned post hoc contrasts of each dose vs. vehicletreated control groups using Dunn’s method. The false discovery rate was corrected for using the Benjamini, Hochberg, and Yekutieli method.
Within an age group, signiﬁcant differences (P < 0.05) between a given dose and the vehicle response (0 dose) are indicated using asterisks (*).
Differences between age groups at a given dose are indicated by pound signs (#). a, b Total locomotion and fecal output during open-ﬁeld
testing, 30–60 min after injection of CP55940 or vehicle. c Latency to exhibit nociceptive behavior when place on a 52 °C hot plate. d Latency
to withdraw the tail from 46 °C water. e Change in rectal temperature 60 m after injection of drug. f Change in infrared recording of skin/
pelage temperature 60 m after injection of drug.

or 0.8 mg/kg injections. Unfortunately, both of these efﬁcacious
doses fell below the LC-MS/MS detection limits in these samples
(data not shown). To determine whether age-related changes in
endocannabinoid gene expression occur within the mouse cortex
and hypothalamus, we performed qPCR on the following
endocannabinoid targets: CB1 (Cnr1), CB2 (Cnr2), CRIP1α (Cnrip1α),
and FAAH1 (Faah1). Compared with young animals, signiﬁcant
reductions in CB1, CRIP1α, and FAAH1 gene expression were
observed in aged cortical (P = 0.034, 0.047, P = 0.002, respectively),
but not aged hypothalamic tissue samples (Table 1). No signiﬁcant
Published in partnership with the Japanese Society of Anti-Aging Medicine

differences in CB2 (Cnr2) gene expression were detected in either
cortical or hypothalamic tissues.
DISCUSSION
Taken together, these ﬁndings reveal that the effects of CP55940
on thermoregulation and behavior are highly age- and dosedependent. Importantly, CP55940 given to aged mice is signiﬁcantly more efﬁcacious than equivalent doses administered to
young mice, and the dose of 0.1 mg/kg appears to be a key
npj Aging and Mechanisms of Disease (2020) 7
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Fig. 2 Effects of CP55940 Co-administered with the CB1 inverse agonist AM251 on locomotion and fecal output in young–adult (4 m) and
old (22 m) male C57BL/6 mice. Varying doses of CP55940 were administered alone or in a pre-mixed solution with 3 mg/kg of AM251 to
young–adult and old male mice. a, c Total distance moved (a) and total fecal output (c) by young–adult (4 m) mice during 30 m of open-ﬁeld
testing. b, d Total distance moved by old (22 m) mice during 30 m of open-ﬁeld testing. All data have been normalized to the responses of
vehicle-treated age-matched control animals which were tested at the same time. Individual data points for each testing group are overlaid on
Tukey-style boxplots. The lower and upper edges of each box represent the ﬁrst and third quartiles, respectively. The middle horizontal line in
each box depicts the median of that dose/age group. Sample sizes for every treatment group and ﬁgure panel are listed in Supplementary Fig.
5. Signiﬁcant omnibus results were followed by planned post hoc contrasts of each dose vs. vehicle-treated control groups using Dunn’s
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differences (P < 0.05) between a given dose and the vehicle-treated response (0 dose) are indicated using asterisks (*). Differences between
CP55940 alone and CP55940 + AM251 at a given dose are indicated by pound signs (#).

inﬂection point in this differential response. In young mice, our
data indicate that low (<0.01 mg/kg, IP) and high (>0.1 mg/kg, IP)
doses of CP55940 bidirectionally regulate measures of locomotion,
and these increases in total locomotion are not associated with
thigmotactic aversive behavior (Supplementary Fig. 6)19. However,
under the present conditions we did not detect signiﬁcant
CP55940-induced stimulation of locomotor activity in aged mice
at any dose of CP55940 tested. The distinct locomotor responses
observed in both age groups at doses of 0.1 mg/kg CP55940
indicate that continued characterization of this speciﬁc dosing
window may help to clarify these age-dependent effects12,15.
In contrast to the antinociceptive effects of CP55940 at doses
≥0.4 mg/kg, aged mice demonstrated signiﬁcantly enhanced
nociception at a single intermediate dose (0.01 mg/kg) in the
hot-water tail-withdrawal task (Fig. 1d). Although the hot plate
and tail-withdrawal tasks both measure nociception, the tailwithdrawal reﬂex is primarily generated within the spinal cord20,
while the behaviors elicited by the hot plate are generated
supraspinally21. In addition, the hind-paw licking measured in the
hot plate task requires substantially greater motor coordination to
evoke. Therefore, the observation that old mice exhibit enhanced
npj Aging and Mechanisms of Disease (2020) 7

nociception at the single dose of 0.01 mg/kg can be explained by
differences in spinally mediated cannabinoid reception or the
enhanced sensitivity of the tail-withdrawal task. The ability to
detect this effect highlights the importance of selecting tasks with
wide detection ranges and sensitivity when studying hormesis.
Moreover, the age-dependent responses seen in these assays of
nociception further demonstrate the importance of using multiple
endpoints when studying aged animals. Given the high prevalence of elderly patients seeking cannabinoid-based therapeutics for chronic pain, additional studies in these models are greatly
needed.
During extensive vehicle acclimation recordings, both
young–adult (4 m) and old (21–24 m) mice exhibited slight
reductions in core-body and skin/pelage temperatures 60 min
post injection (Supplementary Fig. 2). However, on the day of
behavioral testing, vehicle-treated animals consistently showed
increases in rectal and IR temperatures (Fig. 1d, e). One
explanation for this differential response is that during behavioral
testing, postinjection temperatures were taken immediately
after animals completed open-ﬁeld locomotor assessment. Therefore, it is possible that the hyperthermia observed following
Published in partnership with the Japanese Society of Anti-Aging Medicine
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Fig. 3 Effects of CP55940 co-administered with the CB1 inverse agonist AM251 on nociception and thermoregulation in young–adult
(4 m) and old (22 m) male C57BL/6 mice. Varying doses of CP55940 were administered alone or in a pre-mixed solution with 3 mg/kg of
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have been normalized to the responses of vehicle-treated age-matched control animals which were tested at the same time. Individual data
points for each testing group are overlaid on Tukey-style boxplots. The lower and upper edges of each box represent the ﬁrst and third
quartiles, respectively. The middle horizontal line in each box depicts the median of that dose/age group. Sample sizes for every treatment
group and ﬁgure panel are listed in Supplemental Fig. 5. Signiﬁcant omnibus results were followed by planned post hoc contrasts of each
dose vs. vehicle-treated control groups using Dunn’s method. The false discovery rate was corrected for using the Benjamini, Hochberg, and
Yekutieli method. Within an age group, signiﬁcant differences (P < 0.05) between a given dose and the vehicle-treated response (0 dose) are
indicated using asterisks (*). Differences between CP55940 alone and CP55940 + AM251 at a given dose are indicated by pound signs (#).
Table 1.

Quantitative PCR analysis of gene expression in regions of
brain tissue from young–adult (4 m) and old (22 m) male mice.
Cortex

n

CB1 ± SE

CB2 ± SE

CRIP1 ± SE

FAAH1 ± SE

Young
Aged

6
5

1.00 ± 0.09
0.81 ± 0.13
*P = 0.034

1.00 ± 0.04
0.78 ± 0.20
P = 0.239

1.00 ± 0.22
0.63 ± 0.15
*P = 0.047

1.00 ± 0.09
0.59 ± 0.09
*P = 0.002

Hypothalamus

n

CB1 ± SE

CB2 ± SE

CRIP1 ± SE

FAAH1 ± SE

Young
Aged

6
5

1.00 ± 0.24
0.49 ± 1.30
P = 0.12

1.00 ± 0.46
2.55 ± 0.47
P = 0.06

1.00 ± 0.20
1.09 ± 0.71
P = 0.52

1.00 ± 0.17
0.75 ± 1.03
P = 0.15

Delta–delta CT was calculated using HPRT as the housekeeping control.
Gene expression values for old mice have been normalized to the
young group.
*P ≤ 0.05 t test, young vs aged.

vehicle-treatment in this context is confounded by either
locomotion or stress-induced hyperthermia from open-ﬁeld
testing. Furthermore, the high rectal temperatures recorded in
young vehicle-treated mice following open-ﬁeld testing may
Published in partnership with the Japanese Society of Anti-Aging Medicine

represent a ceiling-effect, precluding the replication of previously
observed hyperthermia induced by low doses of cannabinoids11.
As previously reported, the effects of cannabinoids on thermoregulation may not be limited to brain-stem-mediated mechanisms and may also be inﬂuenced by peripheral vasodilation22.
Thus, we chose to measure skin temperature in addition to corebody temperature. A reduction in temperature of both measures
was noted with high doses of CP55940 in all groups tested.
Consistent with previous studies, no signiﬁcant differences in
locomotion were observed with AM630 alone in this study
(Supplementary Fig. 3). However, we were surprised that the
psychomotor stimulation with low doses of CP55940 was blocked
by either AM251 or AM630. This suggests that both CB1 and CB2
mediate, at least in part, the hormetic-like response. Future studies
comparing the effects of CB1 and CB2 antagonists using cognitive
assays where ultralow doses of cannabinoids have demonstrated
protective effects might further delineate whether the observed
blockade of hormesis is unique to locomotion or extends to other
behaviors in rodents.
It is not currently clear what the mechanism is which increases
responsiveness to this cannabinoid in the aged mice. In this study,
we observed signiﬁcantly decreased CB1 (Cnr1), CRIP1α (Cnrip1α),
and FAAH1 (Faah1) gene expression in cortical tissue samples
from aged mice. This is similar to previous research which
npj Aging and Mechanisms of Disease (2020) 7
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demonstrated CB1 levels vary throughout the lifespan, although
these age-related changes appear to be region-speciﬁc as we did
not detect signiﬁcant gene expression differences in the
hypothalamus23,24. A reduction in receptor expression by aged
animals that show enhanced CB1-dependent physiological
behaviors is perplexing, though there is well-established precedence in other neurotransmitter systems that signaling can be
enhanced in a compensative manner following chronic receptor
blockade25. Based on the data we collected, reductions in the
expression of FAAH1 (Faah1) in the aged cortex suggest that
endocannabinoid agonist levels are elevated in our aged mice.
Coupled with the observed age-related reductions in CRIP1α (a
repressor of constitutive CB1 activation26), these two expressionlevel changes may compensatively elevate cortical CB1 signaling
in the aged mouse brain (Table 1). Future studies of cannabinoid
receptor heterodimerization and biased agonism, which have yet
to be assessed in aged mammals, may also yield beneﬁcial insight
on this matter. In addition, cannabinoids may have increased
access to the central nervous system due to declining blood brain
barrier function in aged animals. During the course of this study,
we attempted to assess this hypothesis by measuring the
pharmacokinetic distribution of CP55940 in two independent
cohorts of young and aged mice following injections of either
0.1 mg/kg or 0.8 mg/kg. Despite the fact that these doses
consistently elicited behavioral effects that signiﬁcantly differed
from vehicle-treated mice, this amount of CP55940 ultimately
proved to be below our detection limits in serum, liver, and wholebrain tissue samples.
Mechanistically, our studies with the CB1 and CB2 inverse
agonists suggest that the psychomotor, thermoregulatory, and
antinociceptive effects of CP55940 at doses of 0.001 and 0.01 mg/
kg, IP are independently mediated by both receptors. Treatment
with AM251 alone produced simultaneous reductions in locomotion and rectal temperature, while greatly increasing fecal output,
suggesting that AM251 at a dose of 3 mg/kg,IP is aversive in
young male mice. The notable observation that CP55940 at
0.01 mg/kg abrogates the antinociceptive effects of AM251 in
young males (Fig. 3a) suggests that this dose of CP55940 in
combination with AM251 may restore tonic endocannabinoid
activity to baseline levels. The importance of maintaining tonic
endocannabinoid signaling has been discussed in detail previously, and the limited effect of AM251 administration, by itself,
suggests that the age-dependent responses we observed may be
due to elevated endocannabinoid tone27. As discussed, our aged
animals exhibited signiﬁcant decreases in FAAH1 and CRIP1α
(Table 1). These results suggest that both increased anandamide
levels and CB1 may signaling occur in the aged cortex. Taken
together, these ﬁndings may partially explain the enhanced
responses and baseline differences observed between age groups
(Fig. 1c). The fact that CB1 antagonism rescues many of the
behavioral changes observed with high doses of CP55940 in both
the young and old mice supports a substantial role for this
signaling pathway throughout the lifespan. However, the failure of
AM251 coadministration to rescue the reduction in fecal output
seen at the highest dose (0.8 mg/kg, IP) of CP55940 tested (Fig.2c,
d) suggests a CB1-independent mechanism, and may be due to
interactions with the TRPV1 receptor as recently reported28.
We were surprised that the effects of CP55940 were not sexspeciﬁc, as studies of either aging or cannabinoids often report
pronounced sex-dependent behavioral proﬁles29–32. Moreover,
studies of nociception and pain responses also commonly show
sex-dependent effects33,34, as well as known sex-speciﬁc differences in cannabis abuse and physiological responses following
cannabis consumption in humans35,36. These changes are
hypothesized to be driven, in part, by differences in muscle mass
and fat tissue distribution. In this study, we did not control for
changes in body composition, estrous state, or the stage of
reproductive senescence within our young or aged cohorts, but
npj Aging and Mechanisms of Disease (2020) 7

weight was consistently recorded and all drugs were administered
at weight-adjusted doses (Supplementary Fig. 2). Our data suggest
that the psychostimulatory effects at low doses and robust
inhibitory effects at high doses of this synthetic cannabinoid are
more strongly inﬂuenced by age than sex in mice.
This study offers substantial evidence that the behavioral and
physiological effects of CP55940 are highly age-dependent,
though several additional considerations remain to be addressed.
Speciﬁcally, the current experiments were restricted a highly
potent synthetic cannabinoid known to agonize both CB1 and
CB2. Despite its high afﬁnity for these receptors, high doses of
CP55940 have been shown to modulate other receptors and effect
physiological functions in cells that lack CB1 or CB237. The
expansive endocannabinoidome presents numerous additional
targets, such as the previously mentioned TRPs or biosynthetic/
metabolizing enzymes, which are also likely involved in mediating
the diverse effects of CP5594038. In addition, though the
consumption of synthetic cannabinoids is increasing39, the use
of cannabis and isolated phytocannabinoids is far more common.
Many phytocannabinoids exhibit unique pharmacological proﬁles
that target both canonical CB1 and CB2 endocannabinoid
receptors as well as other nonclassical endocannabinoid targets38.
Accordingly, expanded studies on the age-dependent effects of
cannabis-derived compounds such as THC and non-psychoactive
constituents like CBD and terpenes are now greatly needed.
Rising healthcare costs coupled with the increased availability
of cannabinoid-based substances marketed as therapeutics have
put elderly patients in a particularly vulnerable position3. Although
the aging process in humans and rodents is multifaceted and
exceedingly diverse, reduced physical activity, sleep disturbance,
and chronic pain are some of the most commonly reported
conditions in advanced age. This study indicates that in mice, the
synthetic cannabinoid CP55940 exhibits bidirectional and
behavior-speciﬁc effects that are greatly inﬂuenced by the age
of the subject. Therefore, additional studies are required to discern
the mechanistic basis for this increased responsiveness in aged
rodents and to determine whether these age-dependent effects
are species and/or compound-speciﬁc. In the wake of rapidly
shifting policies affecting access to cannabinoids worldwide,
additional preclinical evidence in aged models will be vital to
anticipate potential effects these substances may have on aging
populations.
METHODS
Animals
All procedures were approved by the University of Mississippi Institutional
Animal Care and Use Committee (IACUC). Experimental cohorts consisted
of two age groups: 2–4 months (young–adult) and 21–24 months (old) of
age. Experiments were performed on male and female C57BL/6NHsd mice
acquired from Envigo (Cat. #: 044) or C57BL/6 mice from the National
Institutes of Aging Aged Rodent Colony. A priori power analysis indicated
that statistically signiﬁcant differences based on a medium effect (Cohen’s
f > 0.25) could be detected with group sizes n > =10. The total number of
animals used for this study is listed in Supplementary Fig. 4. All animals
were housed in the AALAC-accredited University of Mississippi Animal
Facility and given access to food (Cat. #: 7001, Envigo Teklad 4% Fat
Rodent Diet) and tap-water ad libitum for the duration of experiments.
Mice were group-housed (four mice/cage) in climate-controlled rooms
(30–40% relative humidity, 21–23 °C) under a 12:12 “reverse” light cycle
(lights OFF at 8:00am and ON at 8 pm). Upon arrival into the facility,
animals were immediately group-housed in 75 in2 clear polycarbonate
cages (Cat. #: AN76, Ancare) with 1/8” corn-cob bedding and environmental enrichment (Cotton Nestlets, Ancare, and Crink’l Nest, The
Andersons Lab Bedding) then allowed to acclimate to the facility for
7 days before experimentation. Following this week of acclimation, animals
were weighed, ﬁtted with a metal ear tag (Cat. #: INS1005-1LSZ, Kent
Scientiﬁc) and randomized into balanced experimental treatment groups
based on body weight. Mice were checked daily, and clean cages were
Published in partnership with the Japanese Society of Anti-Aging Medicine

E.L. Hodges et al.

7
replaced every week. All experiments and procedures were performed
under dim red light (<1 lux) during the animals’ active period.

Blinding
The experimenter was blinded to all treatment groups during drug
administration and experimentation through the use of arbitrarily coded
drug containers.

Drugs, dosing, and administration
The synthetic cannabinoid CP55940 (Cat. #: 0949, Tocris) was initially
diluted in 100% ethanol (Cat. #: 2701, Decon Labs) to a stock concentration
of 10 mg/mL and kept at −20 °C. The CB1 antagonist, AM251 (Cat. #: 1117,
Tocris) was initially diluted in 100% ethanol (Cat. #: 2701, Decon Labs) to a
stock concentration of 10 mg/mL and kept at −20 °C. The CB2 antagonist,
AM630 (Cat. #: 1120, Tocris) was initially diluted in 66.6% ethanol (Cat. #:
2701, Decon Labs) and 33.3% dimethyl sulfoxide (DMSO, Cat. #: 276855,
Sigma-Aldrich) to a stock concentration of 6.66 mg/mL and kept at −20 °C.
On the day of each experiment, fresh vehicle solution was prepared by ﬁrst
dissolving Kolliphor EL (formerly known as Cremophor EL, Cat. #: C5135500G, Sigma Life Science) in 100% ethanol, then adding sterile 0.9% HSP
pH 7.4 saline (Cat. #: 00409488810, Hospira) in a ratio of (1:1:18).
Experiments using AM251 or AM630 were performed by pre-mixing either
AM251 or AM630 with respective doses of CP55940 prior to injection. All
drug mixtures were administered at a volume of 1 mL/100 g body weight.
During testing, the animal’s temperature and weight were recorded
then a body weight-adjusted dose of vehicle or CP55940 was administered
via intraperitoneal (IP) injection using a 1 mL syringe (Cat. # 309602,
Becton, Dickinson and Company [BD]) and a 25 gauge needle (0.5 ×
16 mm, Cat. # 305122, BD).

16 × 16 photobeam array (Photobeam Activity System, San Diego
Instruments) or recorded using a ceiling-mounted camera. Locomotion
in the X and Y directions were quantiﬁed using beam breaks or softwarebased tracking (Ethovision XT-13, Noldus). During recording, four openﬁeld arenas were used simultaneously, and each arena was shielded on
three sides by 60-cm black plastic dividers so that animals could not see
each other. When administered at high doses, the psychoactive effects of
CP55940 are pronounced from 10 to 120 min. Thus, locomotor activity was
measured continuously for 30 min, beginning 30 min after drug or vehicle
injection. Beam breaks in the X and Y directions were sampled every 5 s for
30 min and then exported to spreadsheets at the conclusion of testing.
Peripheral locomotion was deﬁned as any locomotion which occurred in
the outermost 50% of the open-ﬁeld arena. After removal from the open
ﬁeld, animals were brieﬂy (1–5 min) placed into temporary cages before
testing on the hot plate.

Nociception—hot plate
Nociception was measured by placing a single mouse on top of a
preheated 52 °C thermal block (Cat. #: PE34, IITC Life Sciences), and
recording the latency to withdraw and/or lick their hind paws. During
testing, a hollow clear-plastic cylinder 25 cm in diameter by 35 cm high
was placed on top of the heated thermal block to prevent animals from
leaving the hot plate. Animals were placed in the cavity of the plastic
cylinder directly in contact with the hot plate and closely monitored for
nociceptive responses. Based on preliminary experiments, we concluded
that the latency to lick the hind paws was the most reliable indicator of
nociception. Immediately after licking their hind paws, the timer was
stopped and the animal was removed from the hot plate and placed back
into a temporary cage. If an animal failed to respond to the thermal
stimulus in 45 s, the timer was stopped and the animal was rapidly
removed from the hot plate to prevent tissue damage.

Acclimation
On the day of behavioral testing, all animal cages were placed onto a
plastic or metal cart and relocated to the testing room where they were
allowed to acclimate for 3 h prior to testing. Throughout the acclimation
and testing periods, the room remained dark and white noise was
continuously played at a volume of ~60 db.

Nociception—hot-water tail withdrawal
Several cohorts of male and female mice were also tested using a hotwater bath preheated to 46 °C. After testing on the hot plate, animals were
allowed a 90-s recovery period, then gently scruffed by the nape of the
neck and their tails were dipped 1/3 from the tip into heated water. The
latency to withdraw the tail was manually recorded using a stopwatch.

Body weight
Body weight was measured at the start of every experimental procedure to
ensure accurate drug administration and as an endpoint for exclusion in
the event that an animal’s mass decreased >10% in a week. Animals were
gently removed from their cages by lightly gripping the base of their tail
and placed into a lidless pipette-tip box on top of the balance. Once the
animal ceased, moving the mass was recorded. In between recordings, the
pipette-tip box was wiped clean with ethanol, dried with a paper towel,
and the balance was tared.

Rectal and pelage/surface temperature
Rectal temperature was measured using a Digi-Sense Advanced Precalibrated Thermocouple Thermometer (Cat. #: EW-20250-91, Kent Scientiﬁc)
which was connected to a 1.9 cm × 0.165 cm rectal probe (Cat. #: RET-3,
Kent Scientiﬁc). Before measurement, the rectal probe was cleaned using
70% ethanol, dried, and lightly lubricated with petroleum jelly. Animals
were brieﬂy immobilized on the top of a metal cage lid, and then securely
restrained by gripping the scruff (nape of the neck). After conﬁrming the
animal’s identiﬁcation/ear tag, the rectal probe was gently inserted 1.9 cm
into the animal’s rectum. Once a stable measurement was achieved
(~3–5 s), the temperature was recorded.
Skin/pelage temperature was measured via infrared thermography at
the dorsal pelvis using a FLIR Non-Contact Infrared Spot Thermal Camera
(Cat. #: TG165, FLIR). Emissivity was set to 0.85, as suggested previous
research40. Immediately after weighing, while the animal was standing still
and upright in an empty pipette-tip box, the thermal camera was held
directly above the animal exactly 10 cm away from the animal’s skin. Once
a stable measurement was achieved (~3–5 s), the temperature was
recorded.

Gene expression—qPCR
Cortical and hypothalamic RNA was isolated using the RNA-easy mini kit
(Qiagen) and converted to cDNA using High-Capacity RNA-to-cDNA kit
(Applied Biosystems). RT-PCR was performed using TaqMan Universal PCR
Master mix (Life Technologies) and TaqMan validated primers
(Mm01212171_s1 (Cnr1), Mm02620087_s1 (Cnr2), Mm01187898_m1
(Cnrip1α), Mm00515684_m1 (Faah1), Mm03024075_m1 (Hprt)) on the
CFX connect real-time PCR detection system (Bio-Rad). Delta–delta CT was
then calculated using HPRT as the housekeeping gene. The experimenter
was unaware of age group during testing, and was unblinded during
delta–delta CT analysis.

Experimental timeline
After ear-tagging and enrollment into treatment groups, a 6-day
acclimation period was begun. Initially, animals were acclimated for 3 days
to handling, weighing, and temperature measurement with the rectal
probe and IR camera. Next, the animals were acclimated for 3 days to all of
the previous procedures, as well as IP injection of vehicle (1:1:18, Ethanol:
Kolliphor EL:Saline) and a follow-up 60 m temperature recording after the
initial injection. Drug administration and behavioral experiments were
performed on the 7th day. In an effort to reduce animal number, mice
were given a wash-out period of 7 days and reenrolled into the study
design using a Latin square approach. (Supplementary Fig. 2). Subsequent
rounds of testing used only a 3-day acclimation period, wherein the
animals receive vehicle injections and 60 m follow-up temperature
recordings. On the day of re-testing, animals were randomly assigned to
doses which they had not previously received and the experimenter was
again blinded to the treatment groups.

Locomotion—open ﬁeld

Data analysis, statistics, and exclusions

Locomotor activity was measured by placing a single mouse into a lidless
clear-plastic open-ﬁeld arena (41 × 41 × 38 cm), which was surrounded by a

Data analysis was performed, collected, and analyzed using a combination
of Microsoft Excel (v2016, Microsoft), RStudio (v.1.1.456, RStudio Team),
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MATLAB (r2019a, MathWorks), PAS (v2.0.3, San Diego Instruments), PAS
Data Reporter (v1.0.1.0, San Diego Instruments), Ethovision XT (v13,
Noldus), and G*Power (v3.141).
Prior to omnibus testing, all data for a given measurement were tested
for outliers, which was deﬁned as those points that were greater or less
than three interquartile ranges above or below the third and ﬁrst
interquartile ranges within a single-treatment group. After exclusion of
these points, which are listed in Supplementary File 1, data from each
measurement were assessed for a normal distribution (Shapiro–Wilk
test) and equal variance (Levene test). Since all measures observed failed
these tests, simple main effects and interactions were assessed using the
nonparametric Scheirer–Ray–Hare (S–R–H) test. A priori signiﬁcance was
set at α = 0.05. Signiﬁcant main effects detected in S–R–H tests were
followed by additional post hoc testing using Dunn’s many-to-one
method, which is ideal for comparing multiple dose responses to
vehicle/control treatments. The false discovery rate was corrected for
using the Benjamini, Hochberg, and Yekutieli method. All outliers, main
effects, and post hoc analyses are included in Supplementary Files 1–3.
In addition, notes regarding injection performance (by the experimenter)
were kept during all procedures, and were the primary determinant for
other exclusions. To mitigate the effects of repeated testing, such as in
the case of animals shown in Fig. 2, data in this ﬁgure have been
normalized to the responses of vehicle-treated animals that were tested
at the same time.

Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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